José Miguel Velázquez-López
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
José Miguel Velázquez-López has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Rafael Castillo
Departamento de Farmacia, Facultad de Química, Universidad Nacional Autónoma de México, Mexico City 04510, Mexico
3 shared publications Alicia Hernández-Campos
Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, México, CDMX 04510, Mexico
2 shared publicationsLilián Yépez-Mulia
Unidad de Investigación Médica en Enfermedades Infecciosas y Parasitarias, IMSS, México, CDMX 06720, Mexico
2 shared publicationsPaulina Flores-Carrillo
Facultad de Química, Departamento de Farmacia, Universidad Nacional Autónoma de México, México, CDMX 04510, Mexico
2 shared publications- Alfredo Rosas-Sánchez
Université de Toulouse, UPS, and CNRS, LHFA UMR 5069, 118 route de Narbonne, 31062, Toulouse, France
1 shared publication Alfredo Téllez-Valencia
Facultad de Medicina y Nutrición, Centro de Investigación en Alimentos y Nutrición, Universidad Juárez del Estado de Durango, Durango 34000, Mexico
1 shared publication
Latest Publications
- Open Access
Novel Mixed-Type Inhibitors of Protein Tyrosine Phosphatase 1B. Kinetic and Computational Studies
The Atlas of Diabetes reports 415 million diabetics in the world, a number that has surpassed in half the expected time the twenty year projection. Type 2 diabetes is the most frequent form of the disease; it is characterized by a defect in the secretion of insulin and a resistance in its target organs. In the search for new antidiabetic drugs, one of the principal strategies consists in promoting the action of insulin. In this sense, attention has been centered in the protein tyrosine phosphatase 1B (PTP1B), a protein whose overexpression or increase of its activity has been related in many studies with insulin resistance. In the present work, a chemical library of 250 compounds was evaluated to determine their inhibition capability on the protein PTP1B. Ten molecules inhibited over the 50% of the activity of the PTP1B, the three most potent molecules were selected for its characterization, reporting Ki values of 5.2, 4.2 and 41.3 µM, for compounds 1, 2, and 3, respectively. Docking and molecular dynamics studies revealed that the three inhibitors made interactions with residues at the secondary binding site to phosphate, exclusive for PTP1B. The data reported here support these compounds as hits for the design more potent and selective inhibitors against PTP1B in the search of new antidiabetic treatment.
Open AccessNovel Mixed-Type Inhibitors of Protein Tyrosine Phosphatase 1B. Kinetic and Computational Studies
The Atlas of Diabetes reports 415 million diabetics in the world, a number that has surpassed in half the expected time the twenty year projection. Type 2 diabetes is the most frequent form of the disease; it is characterized by a defect in the secretion of insulin and a resistance in its target organs. In the search for new antidiabetic drugs, one of the principal strategies consists in promoting the action of insulin. In this sense, attention has been centered in the protein tyrosine phosphatase 1B (PTP1B), a protein whose overexpression or increase of its activity has been related in many studies with insulin resistance. In the present work, a chemical library of 250 compounds was evaluated to determine their inhibition capability on the protein PTP1B. Ten molecules inhibited over the 50% of the activity of the PTP1B, the three most potent molecules were selected for its characterization, reporting Ki values of 5.2, 4.2 and 41.3 µM, for compounds 1, 2, and 3, respectively. Docking and molecular dynamics studies revealed that the three inhibitors made interactions with residues at the secondary binding site to phosphate, exclusive for PTP1B. The data reported here support these compounds as hits for the design more potent and selective inhibitors against PTP1B in the search of new antidiabetic treatment.
- 1 September 2016
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 26 (17) , 4377-4381
Synthesis and trypanocidal activity of novel benzimidazole derivatives
- 1 September 2016
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 26 (17) , 4377-4381
Synthesis and trypanocidal activity of novel benzimidazole derivatives